Schonfeld Strategic Advisors LLC decreased its position in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) by 95.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 3,911 shares of the company's stock after selling 82,864 shares during the quarter. Schonfeld Strategic Advisors LLC's holdings in MoonLake Immunotherapeutics were worth $212,000 at the end of the most recent quarter.
Other large investors also recently modified their holdings of the company. Barclays PLC lifted its stake in shares of MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company's stock valued at $283,000 after buying an additional 5,229 shares in the last quarter. Congress Asset Management Co. lifted its stake in shares of MoonLake Immunotherapeutics by 9.5% during the 4th quarter. Congress Asset Management Co. now owns 72,993 shares of the company's stock valued at $3,953,000 after buying an additional 6,352 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new position in shares of MoonLake Immunotherapeutics during the 4th quarter valued at $244,000. Rice Hall James & Associates LLC lifted its stake in shares of MoonLake Immunotherapeutics by 47.3% during the 4th quarter. Rice Hall James & Associates LLC now owns 111,133 shares of the company's stock valued at $6,018,000 after buying an additional 35,664 shares in the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of MoonLake Immunotherapeutics by 18.4% during the 4th quarter. Teacher Retirement System of Texas now owns 6,532 shares of the company's stock valued at $354,000 after buying an additional 1,013 shares in the last quarter. Hedge funds and other institutional investors own 93.85% of the company's stock.
MoonLake Immunotherapeutics Price Performance
Shares of MoonLake Immunotherapeutics stock traded up $1.58 during trading hours on Monday, reaching $39.20. The company's stock had a trading volume of 270,325 shares, compared to its average volume of 356,007. The firm has a 50 day moving average price of $38.40 and a 200-day moving average price of $44.65. MoonLake Immunotherapeutics has a one year low of $31.42 and a one year high of $58.26. The stock has a market cap of $2.51 billion, a P/E ratio of -30.39 and a beta of 1.31.
MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last posted its earnings results on Monday, May 12th. The company reported ($0.63) earnings per share for the quarter, topping analysts' consensus estimates of ($0.76) by $0.13. During the same quarter in the prior year, the company earned ($0.22) earnings per share. As a group, sell-side analysts forecast that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.
Analyst Ratings Changes
MLTX has been the topic of a number of research reports. The Goldman Sachs Group reduced their price target on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a "buy" rating on the stock in a report on Thursday, February 27th. Royal Bank of Canada initiated coverage on shares of MoonLake Immunotherapeutics in a report on Tuesday, March 18th. They issued an "outperform" rating and a $67.00 price target on the stock. HC Wainwright reiterated a "buy" rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a report on Thursday, February 27th. Wolfe Research upgraded shares of MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target on the stock in a report on Monday. Finally, Wedbush reiterated an "outperform" rating and issued a $80.00 price target (up from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Eight investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $78.71.
Read Our Latest Analysis on MLTX
MoonLake Immunotherapeutics Profile
(
Free Report)
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.
See Also
Before you consider MoonLake Immunotherapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MoonLake Immunotherapeutics wasn't on the list.
While MoonLake Immunotherapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
